Baricitinib
Tags:
drug
small molecule
investigational
approved
PubChem: 44205240 44205240 DrugBank: DB11817 DB11817 ATC: L04AA37 L04AA37 Related interactions
Related publications
Title
Author
Type
Treatments for COVID-19: emerging drugs against the coronavirus Francesco Potì, Cristina Pozzoli , Maristella Adami, Enzo Poli, Lucio G. Costa
Review
A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19) Maryam Rameshrad, Majid Ghafoori, Amir Hooshang Mohammadpour, Mohammad Javad Dehghan Nayeri & Hossein Hosseinzadeh
Review
COVID-19: An Update about the Discovery Clinical Trial Jean Jacques Vanden Eynde
Comment
Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste James T. Gordy, Kaushiki Mazumdar, Noton K. Dutta
Other
Review of trials currently testing treatment and prevention of COVID-19. P. C. Fragkou, D. Belhadi, N. Peiffer-Smadja, C. D. Moschopoulos, F. X. Lescure, H. Janocha, E. Karofylakis, Y. Yazdanpanah, F. Mentré, C. Skevaki, C. Laouénan, S. Tsiodras
Review
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Xiuhong Zhang, Yan Zhang, Weizhen Qiao, Ji Zhang, Zhigang Qi,
Research
Baricitinib plus Standard of Care for Hospitalised Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomized, Placebo-Controlled Trial. E. W. Ely, A. V. Ramanan, C. E. Kartman, S. de Bono, R. Liao, M. L. B. Piruzeli, J. D. Goldman, J. F. K. Saraiva, S. Chakladar, V. C. Marconi,
Research
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis P. W. Horby, J. R. Emberson, M. Mafham, M. Campbell, L. Peto, G. Pessoa-Amorim, E. Spata, N. Staplin, C. Lowe, D. R. Chadwick, C. Brightling, R. Stewart, P. Collini, A. Ashish, C. A. Green, B. Prudon, T. Felton, A. Kerry, J. K. Baillie, M. H. Buch, J. N. Day, S. N. Faust, T. Jaki, K. Jeffery, E. Juszczak, M. Knight, W. S. Lim, A. Montgomery, A. Mumford, K. Rowan, G. Thwaites, R. Haynes, M. J. Landray,
Research
Target
Target affiliation
Drug
Type
Result
Target
Target affiliation
Drug
Type
Result
Name
Synonyms
Genes
Origin
Name
Synonyms
Genes
Origin
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Name
Synonyms
PubChem
DrugBank
RCSB PDB
ATC
Title
Authors
DOI
Source
Article type
Date
Title
Authors
DOI
Source
Article type
Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
Title
Status
Phases
Start Date
Prim. Comp. Date
Comp. Date
First Post. Date
CORDITE (CORona Drug InTEractions database) collects and aggregates data from PubMed, MedRxiv, BioRxiv, ChemRxiv and PMC for SARS-CoV-2. Its main focus is set on drug interactions either addressing viral proteins or human proteins that could be used to treat COVID.
It collects and provides up-to-date information on computational predictions, in vitro, as well as in vivo study data.
The information provided is for research only and we cannot guarantee the correctness of the data.
Please contact dominik.heider@uni-muenster.de for further information.
Programmable access
There is an open API for access programmatically to the database. The API will print a JSON output:
Interactions
https://cordite-api.uni-muenster.de/api.php?action=list&table=interaction Targets
https://cordite-api.uni-muenster.de/api.php?action=list&table=target Drugs
https://cordite-api.uni-muenster.de/api.php?action=list&table=drug Publications
https://cordite-api.uni-muenster.de/api.php?action=list&table=publication Clinical trials
https://cordite-api.uni-muenster.de/api.php?action=list&table=clinical_trial
